Vir Biotechnology, Inc. VIR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $65.5M+214% | $68.56M-7.6% | $16.86M-78.6% | $19M-75.9% | $20.86M-73.8% | ||
| —— | —— | —— | $18.26M-76.6% | $20.08M-74.5% | ||
| $446.24M-15.0% | $455.97M-10.0% | $473.7M-7.0% | $517.42M+12.7% | $525.02M+0.5% | ||
| $91.47M-14.2% | $92.07M-22.6% | $95.16M-28.7% | $98.67M-33.7% | $106.65M-35.0% | ||
| $537.57M-19.5% | $547.88M-17.2% | $565.42M-17.8% | $625.42M-2.8% | $667.49M-4.7% | ||
| -$472.07M+27.0% | -$479.33M+18.4% | -$548.56M+9.9% | -$606.42M-7.4% | -$646.63M-4.1% | ||
| -720.8%+2,379pp | -699.2%+92.1pp | -3,253.6%-2,479pp | -3,191.7%-2,476pp | -3,099.7%-2,320pp | ||
| $29.73M-56.0% | $41.56M-35.1% | $49.17M-29.6% | $56.47M-21.8% | $67.58M-4.8% | ||
| -$442.35M+23.6% | -$437.77M+16.3% | -$499.39M+7.4% | -$549.95M-11.7% | -$579.05M-5.3% | ||
| —— | —— | $268K+105% | $277K+103% | -$1.41M+86.7% | ||
| -$442.72M+23.4% | -$437.99M+16.1% | -$499.65M+6.3% | -$550.23M-13.9% | -$577.65M-7.1% | ||
| -676%+2,093pp | -638.9%+64.5pp | -2,963.5%-2,285pp | -2,895.9%-2,284pp | -2,769%-2,091pp | ||
| -$3.12+26.1% | -$3.15+17.5% | -$3.61+7.9% | -$4.00-11.7% | -$4.22-5.2% | ||
| -$460.45M+27.3% | -$467.65M+18.3% | -$536.89M+9.4% | -$594.85M-8.8% | -$633.72M-5.1% | ||
| -703%+2,335pp | -682.1%+89.5pp | -3,184.4%-2,430pp | -3,130.8%-2,438pp | -3,037.8%-2,280pp | ||
| -$472.07M+27.0% | -$479.33M+18.4% | -$548.56M+9.9% | -$606.42M-7.4% | -$646.63M-4.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vir Biotechnology, Inc.'s profit margins?
- Gross margin is 96.1% and operating margin is -720.8%, with a -676.0% net margin.
- Where does Vir Biotechnology, Inc.'s income statement data come from?
- Every line is extracted from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.